



# Kåre Schultz

Incoming President  
& CEO of TEVA

BRINGING DEEP GLOBAL PHARMACEUTICAL EXPERIENCE

# 30

Years of Experience in the  
Pharmaceuticals Industry

2015 – PRESENT:

President & CEO,  
H. Lundbeck A/S

1989 – 2015:

Multiple  
Leadership  
Positions at  
Novo Nordisk A/S

## IMPRESSIVE FINANCIAL RETURNS DURING LUNDBECK TENURE

# 218%



STOCK PRICE  
APPRECIATION 5/5/15 – Present

# \$9.1B



INCREASED MARKET CAP 5/5/15 – Present

## KEY ACCOMPLISHMENTS

### H. Lundbeck A/S

- Lead significant restructuring initiatives
- Launched a robust turnaround strategy focused on driving sustainable global cost structure and operational model
- Conducted a top to bottom evaluation of the business
- Positioned the company to be on track to achieve all-time high revenue and earnings
- Implemented a plan to cut operating costs while targeting new product launches

### Novo Nordisk

- Modernized the company's large scale biologic production
- Implemented a metrics-focused approach to operations
- Lead the company's expansion into the U.S. and Chinese markets

### EDUCATION

- University of Copenhagen
- Masters of Science in Economics

“What drew me to Teva, and what makes Teva different from its peers, is its unique commitment to growing an extensive global reach while continuing to provide new and high-quality treatments for patients and an innovative culture for its employees. I am proud to be joining a company that helps millions of patients around the world on a daily basis with its broad range of generic and specialty drugs and solutions.”